What are the risks, monitoring recommendations, and management strategies for liver toxicity associated with Symtuza (dolutegravir, rilpivirine, tenofovir disoproxil fumarate, emtricitabine)?

Symtuza Liver Toxicity

Symtuza (darunavir/cobicistat/emtricitabine/tenofovir alafenamide) carries a risk of hepatotoxicity, particularly in patients with underlying hepatitis B or C, pre-existing liver disease, or those taking other hepatotoxic medications, and requires baseline liver function testing with ongoing clinical monitoring for signs of liver injury.

Risk Profile

The hepatotoxicity risk with Symtuza stems primarily from its components, particularly the boosted protease inhibitor darunavir. While the provided evidence does not contain specific FDA labeling for Symtuza itself, the individual components carry established hepatotoxicity warnings:

• Rilpivirine (a component in similar fixed-dose combinations): Hepatic adverse events have been reported, with patients having underlying hepatitis B or C infection or marked baseline transaminase elevations at increased risk for worsening or development of transaminase elevations 11

• Dolutegravir (integrase inhibitor, similar class considerations): Hepatotoxicity has been documented, including cases in patients without pre-existing hepatic disease. Drug-induced liver injury leading to liver transplant has been reported with dolutegravir-containing regimens 23

• Tenofovir disoproxil fumarate: Associated with renal toxicity more than hepatotoxicity, though monitoring remains important 4

Pre-Treatment Screening

Mandatory baseline assessments:

• Liver function tests (ALT, AST, bilirubin, alkaline phosphatase)
• Hepatitis B surface antigen and hepatitis C antibody testing
• Document all concomitant medications with hepatotoxic potential
• Assess alcohol consumption history
• Review any prior history of drug-induced liver injury

Contraindications to consider:

• Active hepatitis with significantly elevated transaminases (>5× ULN)
• Decompensated cirrhosis
• Concurrent use of other hepatotoxic medications when alternatives exist
• History of severe drug-induced hepatotoxicity

Monitoring Strategy

For patients WITHOUT pre-existing liver disease:

• Baseline liver function tests required
• No routine scheduled monitoring if baseline normal and asymptomatic 555
• Symptom-triggered testing: Repeat LFTs immediately if fever, malaise, vomiting, jaundice, abdominal pain, or unexplained clinical deterioration occur 555
• Patient education critical: instruct to stop medication and seek immediate evaluation for any hepatitis symptoms 1

For patients WITH chronic liver disease (hepatitis B/C, cirrhosis):

• Baseline liver function tests
• Intensive monitoring schedule 55:
  • Weekly LFTs for first 2 weeks
  • Every 2 weeks for months 2-3
  • Monthly thereafter for first 6 months
  • Then every 3 months if stable
• Consider more frequent monitoring if any upward trend in transaminases

For patients with baseline transaminase elevations:

• If ALT/AST 2-5× ULN: Weekly monitoring for 2 weeks, then every 2 weeks until normalized or stable 55
• If ALT/AST >5× ULN or any bilirubin elevation: Do not initiate therapy until values improve and underlying cause identified

Management of Elevated Liver Enzymes

Mild elevations (ALT/AST <2× ULN):

• Continue therapy
• Repeat testing in 2 weeks
• If stable or decreasing: monitor symptomatically
• If increasing: escalate to more frequent monitoring

Moderate elevations (ALT/AST 2-5× ULN):

• Continue therapy if asymptomatic
• Weekly monitoring for 2 weeks, then biweekly 55
• Investigate alternative causes (viral hepatitis, alcohol, other medications)
• Consider dose adjustment or alternative regimen if progressive

Severe elevations requiring immediate discontinuation:

• ALT/AST >5× ULN in asymptomatic patient 555
• ALT/AST >ULN with hepatitis symptoms (nausea, vomiting, abdominal pain, jaundice) 4
• Any bilirubin elevation above normal range, regardless of symptoms 55
• Signs of hepatic decompensation (ascites, encephalopathy, coagulopathy)

After discontinuation:

1. Stop ALL potentially hepatotoxic antiretrovirals immediately 4
2. Investigate non-drug etiologies (acute viral hepatitis, autoimmune hepatitis, biliary obstruction)
3. Monitor liver function and clinical status closely
4. Continue non-hepatotoxic antiretrovirals if needed for HIV control (consider integrase inhibitors with better hepatic safety profile)
5. Do NOT rechallenge with Symtuza once severe hepatotoxicity occurs

Special Populations

Hepatitis B co-infection:

• Emtricitabine and tenofovir components provide HBV activity
• Critical warning: Discontinuation may cause severe acute exacerbation of hepatitis B
• If Symtuza must be stopped, ensure alternative HBV-active therapy continued
• Monitor HBV DNA and liver function closely during any treatment changes

Hepatitis C co-infection:

• Higher baseline risk for hepatotoxicity 11
• More intensive monitoring required
• Consider treating HCV before or concurrent with HIV therapy when possible

Pregnancy:

• Dolutegravir-based regimens preferred over protease inhibitors in pregnancy 6
• If Symtuza used, maintain standard hepatotoxicity monitoring
• No dose adjustment needed

Drug-Drug Interactions Increasing Hepatotoxicity Risk

Avoid concurrent use with:

• Rifampin (contraindicated with protease inhibitors due to significant drug interactions) 76
• Other hepatotoxic antiretrovirals (nevirapine, efavirenz if alternatives available) 44
• Excessive alcohol consumption 8
• Acetaminophen in high doses
• Anti-tuberculosis drugs (isoniazid, pyrazinamide, rifampin) - requires alternative ART regimen 8

Clinical Pearls

• Hepatotoxicity can occur without pre-existing risk factors - maintain vigilance in all patients 23
• Most severe reactions occur within first 4-8 weeks of therapy 8
• Patient education about warning symptoms is as important as laboratory monitoring 51
• A single case of dolutegravir-induced liver failure requiring transplantation has been reported, emphasizing that severe outcomes, while rare, are possible 3
• In the EuroSIDA cohort study, independently reviewed hepatotoxicity discontinuations were very rare (0.18/1000 person-years for dolutegravir with abacavir), indicating overall low rates of serious hepatic adverse events 9